Published in PLoS One on April 15, 2016
Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy | NCT02994303
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med (2001) 6.94
The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int (2007) 5.15
Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. Cell (2001) 5.12
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med (2006) 3.38
A block of autophagy in lysosomal storage disorders. Hum Mol Genet (2007) 3.28
Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet (2001) 3.23
Stereological estimation of the volume-weighted mean volume of arbitrary particles observed on random sections. J Microsc (1985) 2.85
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol (2007) 2.73
Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev Cell (2011) 2.71
Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol (2005) 2.49
Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch (2005) 2.45
Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med (1973) 2.35
Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J Biol Chem (2006) 2.34
Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int (2002) 2.15
Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol (2013) 2.11
Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest (2007) 2.02
Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol (2006) 1.92
Ca2+ triggers massive exocytosis in Chinese hamster ovary cells. EMBO J (1996) 1.80
The impact of recent stereological advances on quantitative studies of the nervous system. J Neurosci Methods (1986) 1.79
Glomerular Aging and Focal Global Glomerulosclerosis: A Podometric Perspective. J Am Soc Nephrol (2015) 1.76
Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int (1978) 1.56
Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis (2008) 1.53
Cholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npc1 -/- mouse brain. Am J Pathol (2007) 1.46
Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease. Heart (2015) 1.43
A role for synaptotagmin VII-regulated exocytosis of lysosomes in neurite outgrowth from primary sympathetic neurons. J Neurosci (2006) 1.36
Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders. EMBO J (2010) 1.35
A biosynthetic regulated secretory pathway in constitutive secretory cells. J Cell Biol (1996) 1.31
The role of the podocyte in albumin filtration. Nat Rev Nephrol (2013) 1.26
Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int (2010) 1.25
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant (2011) 1.23
Role of lysosomal and cytosolic pH in the regulation of macrophage lysosomal enzyme secretion. Biochem J (1990) 1.15
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant (2009) 1.15
Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int (2004) 1.14
Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int (2008) 1.14
Observations of glomerular epithelial cell structure in patients with type I diabetes mellitus. Kidney Int (1987) 1.06
Membrane repair: Ca(2+)-elicited lysosomal exocytosis. Curr Biol (2001) 1.05
Ca2+-dependent actin coating of lamellar bodies after exocytotic fusion: a prerequisite for content release or kiss-and-run. Ann N Y Acad Sci (2009) 1.02
Renal complications of Fabry disease in children. Pediatr Nephrol (2012) 0.93
Identification of lysosome-associated membrane protein-2 as an activation-dependent platelet surface glycoprotein. Blood (1992) 0.91
Zn2+ efflux through lysosomal exocytosis prevents Zn2+-induced toxicity. J Cell Sci (2014) 0.88
The initial stages of neural regeneration are dependent upon intracellular calcium levels. Neuroscience (1992) 0.85
Silver-enhanced immunogold scanning electron microscopy using vibratome sections of rat kidneys: detection of albumin filtration and reabsorption. Med Mol Morphol (2011) 0.83
Brief exposure to copper activates lysosomal exocytosis. Cell Calcium (2015) 0.82
Podocyte hypertrophy precedes apoptosis under experimental diabetic conditions. Apoptosis (2015) 0.81
A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. Cardiovasc Pathol (2009) 0.80
Bile acid-dependent vesicular transport of lysosomal enzymes into bile in the rat. Gastroenterology (1993) 0.80
Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. PLoS One (2014) 0.78
Isolated rat alveolar type II cells protrude intracellular lamellar bodies by forming bubble-like structures during surfactant secretion. Cell Tissue Res (2008) 0.77
Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. PLoS One (2014) 0.78
Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. Nephrol Dial Transplant (2017) 0.78
Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times. Pediatr Nephrol (2016) 0.75
Low Birth Weight and Risk of Progression to End Stage Renal Disease in IgA Nephropathy-A Retrospective Registry-Based Cohort Study. PLoS One (2016) 0.75
Reduced α-galactosidase A activity in zebrafish ( mirrors distinct features of Fabry nephropathy phenotype. Mol Genet Metab Rep (2022) 0.75
Erratum to: Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times. Pediatr Nephrol (2017) 0.75
Pathomechanisms of renal Fabry disease. Cell Tissue Res (2017) 0.75